Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BGM vs ETON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ETON Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

ETON Overall Winner 6-Pillar Tally: BGM 1 – 5 ETON Matrix Metrics: BGM 2 – 8 ETON

As of Nov 20, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas ETON carries 35.9/100 (SELL) at $60.85 (18.4x Forward P/E, 31.3% operating margin).

  • Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. ETON 35.9/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -23.4% operating margin) and revenue trajectory (+157.9% vs. +69.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs ETON
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
ETON NASDAQ Head-to-Head Winner
Eton Pharmaceutcials, Inc. Common Stock
Pharmaceutical Preparations
$60.85
-0.83% 1D
Market Cap $1.8B
TTM Revenue $141M
Forward P/E 18.4x
Beta / 30D Vol 0.71β · 98% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 8.0 Fund 37.0 Flow 68.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 56
RSI-14: 55.8 · SMA20: $57.62 · SMA50: $55.67

6-Pillar Scorecard Institutional Category Breakdown (BGM 1 – 5 ETON)

Columns: Metric · BGM · ETON
1. Valuation Multiples ETON
Forward P/E N/M 18.4x
Trailing P/E N/M 39.8x
PEG Ratio N/M N/M
EV / Revenue 2.3x 12.3x
2. Growth & Scale ETON
Revenue Growth (YoY) +69.8% +157.9%
Earnings Growth (YoY) +0.0% -12.6%
TTM Revenue (USD) $48M $141M
Market Cap $108.6M $1.8B
3. Profitability & Quality ETON
Gross Margin 16.9% 71.2%
Operating Margin -23.4% 31.3%
Net Profit Margin -44.2% 35.4%
Return on Equity (ROE) -7.4% 90.6%
4. Balance Sheet & Cash Flow ETON
Cash Generation (TTM) -$9.2M EBITDA $20M
Cash Flow Margin -19.3% EBITDA Mgn 14.2%
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ETON
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 343.6% (100th %ile)
Put/Call OI Skew N/A 0.03x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat BGM
OpEx & R&D Intensity 40.3% of Rev ($19M) 39.9% of Rev ($56M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (2) vs ETON (8)
Institutional Metric BGM ETON Criterion Row Edge
Market Capitalization
Scale
$108.6M $1.8B Larger Scale ETON
Trailing P/E Ratio
Valuation
N/M 39.8x Lower Multiple ETON
Forward P/E Ratio
Valuation
N/M 18.4x Lower Multiple ETON
Revenue Growth (YoY)
Growth
+69.8% +157.9% Higher Growth ETON
Operating Margin (TTM)
Profitability
-23.4% 31.3% Higher Margin ETON
Net Profit Margin
Profitability
-44.2% 35.4% Higher Margin ETON
Return on Equity (ROE)
Capital Efficiency
-7.4% 90.6% Higher ROE ETON
52-Week Range Position
Momentum
74% ($0–$11) 83% ($14–$71) Stronger Trend ETON
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol 0.71β · 98% Vol Lower Realized Risk BGM
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite BGM
Trailing 12M Revenue (USD)
Operating Scale
$48M $141M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% 71.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 12.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) $20M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ETON +32.63 pp
BGM: -21.57% · ETON: +11.06%
3M Horizon BGM +2626.36 pp
BGM: +2673.93% · ETON: +47.57%
6M Horizon BGM +2856.26 pp
BGM: +2962.79% · ETON: +106.53%
1Y Horizon ETON +270.57 pp
BGM: -5.77% · ETON: +264.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs ETON. Trailing 12-month operating profitability (BGM -23.4% vs ETON 31.3%) and valuation multiples (BGM N/M vs ETON 18.4x Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
ETON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$141M
Gross Margin71.2%
Op. Margin31.3%
ROE / Fwd P/E90.6% · 18.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ETON CONSOLIDATION
63d in phase · OBV DISTRIBUTION
Current IV 343.6%
IV Percentile 100th %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ETON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
ETON Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.8B market capitalization and 31.3% operating margin.
OpEx & R&D Reinvestment 39.9% of Rev ($56M)
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs ETON Key Questions & Quantitative Answers

As of Nov 20, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas ETON carries 35.9/100 (SELL) at $60.85 (18.4x Forward P/E, 31.3% operating margin). Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. ETON 35.9/100 SELL), ETON captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -23.4% operating margin) and revenue trajectory (+157.9% vs. +69.8% YoY).

ETON leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with ETON at +157.9% YoY revenue growth and -12.6% YoY earnings growth on $141M TTM revenue (71.2% gross margin, 31.3% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $141M for ETON. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 39.9% of Rev ($56M) (0 disclosures) for ETON.

ETON screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas ETON trades at 18.4x Forward P/E, 39.8x Trailing P/E, N/M PEG, and 12.3x EV/Revenue (14.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus ETON (90.6% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, ETON carries 343.6% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.71β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.